APSR2026-249

Yes
Late-Breaking
Submitted
Oral Presentation
AO06-004
 
 
https://storage.unitedwebnetwork.com/files/1285/1216094-46903-APSR-249-AO06_004_440292.pptx
Format: PPTX Only
 
Format: PDF Only
08. Lung Cancer
4

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Shasha Guan * Tianjin Medical University General Hospital, Department of Medical Oncology Tianjin China
Lingping Kong - Tianjin Medical University General Hospital, Department of Medical Oncology Tianjin China
Linlin Zhang - Tianjin Medical University General Hospital, Department of Medical Oncology Tianjin China
Diansheng Zhong - Tianjin Medical University General Hospital, Department of Medical Oncology Tianjin China
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Shasha
Guan
guanss07@163.com
+8618526422086
31-40
China
Original Research
DNA-PK inhibitor AZD7648 synergizes with osimertinib to overcome acquired resistance in EGFR-mutant non-small cell lung cancer
Maximum 25 words
Abstract Content
Third-generation EGFR-TKIs, represented by osimertinib, are the first-line treatment for EGFR-mutant NSCLC and demonstrate remarkable efficacy. However, acquired resistance limits the long-term therapeutic benefit. Given the complexity of resistance mechanisms, broad-spectrum and effective combination strategies are urgently needed. This study aims to reveal the synergistic inhibitory effect of combining the DNA-PK inhibitor AZD7648 with osimertinib on resistant cells and elucidates the underlying molecular mechanisms.
Osimertinib-resistant (OR) cells were established by continuously inducing EGFR-mutant NSCLC sensitive cell lines (H1975, PC9, HCC827) with osimertinib in vitro. DNA damage was induced by cisplatin in sensitive and OR cells; DNA double strand breaks (DSB) damage extent and the levels of non-homologous end joining (NHEJ) pathway-related proteins were assessed by WB and immunofluorescence. In vitro experiments evaluated the effects of AZD7648 combined with osimertinib on cell proliferation, colony formation and migration. Mechanistically, nuclear-cytoplasmic separation and Co-IP were performed to determine EGFR subcellular localization and its interaction with DNA-PK in resistant cells.
1.After cisplatin-induced DNA damage, OR cells exhibited elevated γH2AX levels compared to sensitive cells, indicating more severe DNA double-strand breaks and delayed repair. Elevated levels of pDNA-PK and 53BP1 indicate enhanced NHEJ activity in OR cells. 2.The combination index (CI < 1) confirmed a synergistic effect between AZD7648 and osimertinib in OR cells. 3.MTT assays showed that the combination suppressed cell proliferation more potently than either agent alone. 4.Colony-formation assays further demonstrated that the combination markedly reduced the clonogenicity of OR cells. 5.Wound healing assays revealed that the combination effectively suppressed cell migration. 6.Nuclear-cytoplasmic separation demonstrated the nuclear translocation of EGFR in OR cells. Co-IP confirmed the interaction between EGFR and DNA-PK.
This study elucidates a novel mechanism of EGFR-TKI resistance, provides a rationale for combining DNA-PK inhibition with osimertinib, and offers new insight into overcoming acquired resistance in NSCLC.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Osimertinib resistant, DNA damage repair, DNA-PK inhibitor
maximum 3 keywords and no abbreviations, separated by commas
 
301